nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.21682/2311-1267-2020-7-4-56-61nodgo-668Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSПерспективы использования пролонгированных препаратов концентратов фактора свертывания крови IX в лечении гемофилии ВProspects for the use of prolonged concentrates of blood clotting factor IX in the treatment of hemophilia Bhttps://orcid.org/0000-0003-0452-0145КонстантиноваВ. Н.KonstantinovaV. N.

Константинова Валерия Николаевна - кандидат медицинских наук, врач-гематолог.191186, Санкт-Петербург, ул. Гороховая, 6а.

Cand. of Sci. (Med.), Hematologist City Center for the Treatment of Hemophilia Patients of City Polyclinic № 37.6a Gorokhovaya St., S.-Petersburg, 191186.

vkonstantinova@yandex.ruhttps://orcid.org/0000-0002-5649-325XАндрееваТ. А.AndreevaT. A.

Кандидат медицинских наук, врач-гематолог, заведующая.191186, Санкт-Петербург, ул. Гороховая, 6а.Author ID: 954196SPIN-код: 8529-6758

Cand. of Sci. (Med.), Hematologist, Head of the City Center for the Treatment of Hemophilia Patients of City Polyclinic № 37.6a Gorokhovaya St., S.-Petersburg, 191186.Author ID: 954196SPIN-code: 8529-6758

spbhc@msn.comhttps://orcid.org/0000-0002-0253-9451КимА. В.KimA. V.

Доктор медицинских наук, профессор, главный врач СПб ГБУЗ «Городская поликлиника № 37».191186, Санкт-Петербург, ул. Гороховая, 6а.

Dr. of Sci. (Med.), Professor, Head of City Polyclinic № 37.6a Gorokhovaya St., S.-Petersburg, 191186.

avkim@mail.ruГородской центр по лечению больных гемофилией СПб ГБУЗ «Городская поликлиника № 37»РоссияCity Center for the Treatment of Hemophilia Patients of City Polyclinic № 37Russian Federation202007012021745661Copyright © Константинова В.Н., Андреева Т.А., Ким А.В., 20212021Константинова В.Н., Андреева Т.А., Ким А.В.Konstantinova V.N., Andreeva T.A., Kim A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/668

Гемофилия В — наследственное заболевание свертывающей системы крови, обусловленное Дефицитом или молекулярными аномалиями фактора свертывания крови IX. Основной метод лечения — внутривенное введение препаратов концентратов фактора свертывания крови IX. Для оптимизации лечения и повышения приверженности пациентов к терапии разработаны концентраты с пролонгированным периодом полужизни.

Hemophilia B is a hereditary disease of the blood clotting system caused by a deficiency or molecular abnormalities of blood clotting factor IX. The main method of treatment is intravenous administration of coagulation factor IX concentrates. To optimize treatment and increase patient adherence to therapy, concentrates with a prolonged half-life have been developed.

гемофилия Вмолекулярные аномалии фактора IXконцентраты с пролонгированным периодом полужизнинонаког альфаэфтренонаког альфаальбутрепенонаког альфалабораторный контрольhemophilia Bmolecular abnormalities of factor IXconcentrates with a prolonged half-lifenonacog alfaeftrenonacog alfaalbutrepenonacog alfalaboratory controlСтатья подготовлена при финансовой поддержке компании CSL Behring.The article was funding by CSL Behring.ReferencesЗозуля Н.И., Кумскова М.А. Протокол диагностики и лечения гемофилии. В кн.: Алгоритмы диагностики и протоколы лечения заболеваний системы крови. Под ред. акад. В.Г. Савченко. Т. 1. М .: Национальный медицинский исследовательский центр гематологии, 2018. С. 333-375.Zozulya N.I., Kumskova M.A. Protocol of diagnosis and treatment of hemophilia. In: Diagnostic algorithms and treatment protocols for diseases of the blood system. Ed. by Academician V.G. Savchenko . M.: National Medical Research Center for Hematology, 2018. Vol. 1. Pp. 333-375. (In Russ.).Мамаев А.Н. Коагулопатии: руководство. М.: ГЭОТАР-Медиа, 2012. 264 с.Mamaev A.N. Coagulopathies: a guide. M.: GEOTARMedia, 2012. 264 p. (In Russ.).Tjarnlund-Wolf A., Lassila R. Phenotypic characterization of haemophilia B - understanding the underlying biology of coagulation factor IX. Haemophilia 2019;25(4):567-74. doi: 10.1111/hae.13804.Tjarnlund-Wolf A., Lassila R. Phenotypic characterization of haemophilia B - understanding the underlying biology of coagulation factor IX. Haemophilia 2019;25(4):567-74. doi: 10.1111/hae.13804.Weyand A.C., Pipe S.W. New therapies for hemophilia. Blood 2019;133(5):389-98. doi: 10.1182/blood-2018-08-872291.Weyand A.C., Pipe S.W. New therapies for hemophilia. Blood 2019;133(5):389-98. doi: 10.1182/blood-2018-08-872291.Carcao M. Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia 2014;20 Suppl 4:99-105. doi: 10.1111/hae.12405.Carcao M. Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia 2014;20 Suppl 4:99-105. doi: 10.1111/hae.12405.Mannucci P.M., Macuso M.E. Investigational drugs for coagulation disorders. Expert Opin Invest Drugs 2013;22(8):945-53. doi: 10.1517/13543784.2013.798302.Mannucci P.M., Macuso M.E. Investigational drugs for coagulation disorders. Expert Opin Invest Drugs 2013;22(8):945-53. doi: 10.1517/13543784.2013.798302.Oldenburg J., Albert T. Novel products for haemostasis - current status. Haemophilia 2014;20(Suppl 4):23-8. doi: 10.1111/hae.12428.Oldenburg J., Albert T. Novel products for haemostasis - current status. Haemophilia 2014;20(Suppl 4):23-8. doi: 10.1111/hae.12428.Metzner H.J., Weimer T., Kronthaler U., Lang W., Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. J Thromb Haemost 2009;102(4):634-44. doi: 10.1160/TH09-04-0255.Metzner H.J., Weimer T., Kronthaler U., Lang W., Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. J Thromb Haemost 2009;102(4):634-44. doi: 10.1160/TH09-04-0255.Santagostino E. Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). Thromb Res 2016 ;141 Suppl 3:S5-8. doi: 10.1016/S0049-3848(16)30415-7.Santagostino E. Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). Thromb Res 2016 ;141 Suppl 3:S5-8. doi: 10.1016/S0049-3848(16)30415-7.Pipe S.W. New therapies for hemophilia. Hematology Am Soc Hematol Educ Program 2016;2016(1):650-656. doi: 10.1182/asheducation-2016.1.650.Pipe S.W. New therapies for hemophilia. Hematology Am Soc Hematol Educ Program 2016;2016(1):650-656. doi: 10.1182/asheducation-2016.1.650.Shapiro A. Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia. Expert Opin Biol Ther 2013;13(9):1287-97. doi: 10.1517/14712598.2013.819339.Shapiro A. Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia. Expert Opin Biol Ther 2013;13(9):1287-97. doi: 10.1517/14712598.2013.819339.Ducore J.M., Miguelino M.G., Powell J.S. Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B. Expert Rev Hematol 2014;7(5):559-71. doi: 10.1586/17474086.2014.951322.Ducore J.M., Miguelino M.G., Powell J.S. Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B. Expert Rev Hematol 2014;7(5):559-71. doi: 10.1586/17474086.2014.951322.Santagostino E., Martinowitz U., Lissitchkov T., Pan-Petesch B., Hanabusa H., Oldenburg J., Boggio L., Negrier C., Pabinger I., von Depka Prondzinski M., Altisent C., Castaman G., Yamamoto K., Alvarez-Roman M.-T., Voigt C., Blackman N., Jacobs I.; PROLONG-9FP Investigators Study Group. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood 2016;127(14):1761-9. doi: 10.1182/blood-2015-09-669234.Santagostino E., Martinowitz U., Lissitchkov T., Pan-Petesch B., Hanabusa H., Oldenburg J., Boggio L., Negrier C., Pabinger I., von Depka Prondzinski M., Altisent C., Castaman G., Yamamoto K., Alvarez-Roman M.-T., Voigt C., Blackman N., Jacobs I.; PROLONG-9FP Investigators Study Group. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood 2016;127(14):1761-9. doi: 10.1182/blood-2015-09-669234.Pelland-Marcotte M.-C., Carcao M.D. Hemophilia in a changing treatment landscape. Hematol Oncol Clin North Am 2019;33(3):409-23. doi: 10.1016/j.hoc.2019.01.007.Pelland-Marcotte M.-C., Carcao M.D. Hemophilia in a changing treatment landscape. Hematol Oncol Clin North Am 2019;33(3):409-23. doi: 10.1016/j.hoc.2019.01.007.Chan A.K., Alamelu J., Barnes C., Chuansumrit A., Garly M.L., Meldgaard R.M., Young G. Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients. Res Pract Thromb Haemost 2020;4(7):1101-13. doi: 10.1002/rth2.12412.Chan A.K., Alamelu J., Barnes C., Chuansumrit A., Garly M.L., Meldgaard R.M., Young G. Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients. Res Pract Thromb Haemost 2020;4(7):1101-13. doi: 10.1002/rth2.12412.Kenet G., Chambost H., Male C., Lambert T., Halimeh S., Chernova T., Mancuso M. E., Curtin J., Voigt C., Li Y., Jacobs I., Santagostino E. Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Thromb Haemost 2016;116(4):659-68. doi: 10.1160/TH16-03-0179Kenet G., Chambost H., Male C., Lambert T., Halimeh S., Chernova T., Mancuso M. E., Curtin J., Voigt C., Li Y., Jacobs I., Santagostino E. Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Thromb Haemost 2016;116(4):659-68. doi: 10.1160/TH16-03-0179Santagostino E., Negrier C., Klamroth R., Tiede A., Pabinger-Fasching I., Voigh C., Jacobs I., Morfini M. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012;120(12):2405-11. doi: 10.1182/blood-2012-05-429688.Santagostino E., Negrier C., Klamroth R., Tiede A., Pabinger-Fasching I., Voigh C., Jacobs I., Morfini M. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012;120(12):2405-11. doi: 10.1182/blood-2012-05-429688.Mancuso M.E., Lubetsky A., Pan-Petesch B., Lissitchkov T., Nagao A., Seifert W., Li Y., Santagostino E. Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B. J Thromb Haemost 2020;18(5):1065-74. doi: 10.1111/jth.14778.Mancuso M.E., Lubetsky A., Pan-Petesch B., Lissitchkov T., Nagao A., Seifert W., Li Y., Santagostino E. Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B. J Thromb Haemost 2020;18(5):1065-74. doi: 10.1111/jth.14778.Hermans C., Marino R., Lambert C., Mangles S., Sommerer P., Rives V., Maro G., Malcangi G. Real-world utilization and bleed rates in patients with haemophilia B who switched to recombinant factor IX Fusion Protein (rIX-FP): a retrospective international analysis. Adv Ther 2020;37(6):2988-98. doi: 10.1007/s12325-020-01300-6.Hermans C., Marino R., Lambert C., Mangles S., Sommerer P., Rives V., Maro G., Malcangi G. Real-world utilization and bleed rates in patients with haemophilia B who switched to recombinant factor IX Fusion Protein (rIX-FP): a retrospective international analysis. Adv Ther 2020;37(6):2988-98. doi: 10.1007/s12325-020-01300-6.Приказ Министерства здравоохранения Российской Федерации от 20.12.2012 № 1238н «Об утверждении стандарта первичной медико-санитарной помощи детям при гемофилии А, гемофилии В (профилактике кровотечений или кровоизлияний при неосложненном течении и после успешной индукции иммунной толерантности)» (Зарегистрировано в Министерстве юстиции Российской Федерации 19.02.2013 № 27187).Order of the Ministry of Health of the Russian Federation from 20.12.2012 № 1238н “On approval of the standard primary health care to children with hemophilia A, hemophilia B (In prevention of bleeding or hemorrhage in uncomplicated and after successful induction of immune tolerance)” (Registered with the Ministry of Justice of the Russian Federation 19.02.2013 № 27187). (In Russ.).Стандарт медицинской помощи больным с наследственным дефицитом фактора VIII, с наследственным дефицитом фактора IX, болезнью Виллебранда. Утвержден Приказом Министерства здравоохранения и социального развития Российской Федерации от 14.11.2007 № 705.Standard of care for patients with hereditary factor VIII deficiency, hereditary factor IX deficiency, and Willebrand’s disease. Approved by the Order of the Ministry of Health and Social Development of the Russian Federation from 14.11.2007 № 705. (In Russ.).Pouplard C., Galinat H., Ternisien C., Jouvan F.B., De Maistre E., Duchemin J., Flaujac C., Hezard N., Grand F., Le Cam-Duchez V., Marlu R., Mourey G., Nedelec F., Pineau-Vincent F., Repesse Y., Stepanian A., Szymezak J., Voisin S., Voyer A. L., Jeanpierre E., Lasne D.; French Study Group on Laboratory Management of bleeding disorders (BIMHO group). Multicentre evaluation of CK Prest® for assaying plasma levels of factor IX fused with albumin (Idelvion®). Haemophilia 2019;25(5):e327-30. doi: 10.1111/hae.13812.Pouplard C., Galinat H., Ternisien C., Jouvan F.B., De Maistre E., Duchemin J., Flaujac C., Hezard N., Grand F., Le Cam-Duchez V., Marlu R., Mourey G., Nedelec F., Pineau-Vincent F., Repesse Y., Stepanian A., Szymezak J., Voisin S., Voyer A. L., Jeanpierre E., Lasne D.; French Study Group on Laboratory Management of bleeding disorders (BIMHO group). Multicentre evaluation of CK Prest® for assaying plasma levels of factor IX fused with albumin (Idelvion®). Haemophilia 2019;25(5):e327-30. doi: 10.1111/hae.13812.Tripodi A., Chantarangkul V., Novembrino C., Peyvandi F. Advances in the treatment of hemophilia: implications for laboratory testing. Clin Chem 2019;65(2):254-62. doi: 10.1373/clinchem.2017.284356.Tripodi A., Chantarangkul V., Novembrino C., Peyvandi F. Advances in the treatment of hemophilia: implications for laboratory testing. Clin Chem 2019;65(2):254-62. doi: 10.1373/clinchem.2017.284356.

The authors declare that there are no conflicts of interest present.